Form 4 for TARS Tarsus Pharmaceuticals, Inc.

Accepted 2026-06-17 16:17:03 ET · period of report 2026-06-15 · accession 0001228684-26-000006 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MT	2026-06-17 16:17	2026-06-15	TARS	LINK WILLIAM J PHD	Dir	S - Sale	$62.12	-12.5K	106.8K	-10%	-$776.5K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-06-15	S	D	10,572	$61.97	108,714	D	—	—	(F1) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. (F2) The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $61.67 to $62.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2	Common	Common Stock	2026-06-15	S	D	1,928	$62.94	106,786	D	—	—	(F1) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. (F3) The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $62.68 to $63.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.